Organigram holds #1 market share in Canada across vapes, milled flower, and concentrates, with leading positions in pre-rolls and edibles. The company has launched its Collective Project and Fetch brands into Illinois and Wisconsin through new distribution partners, expanding its US retail footprint to 11 states. The company demonstrates strong operational execution with a diverse brand portfolio and increasing focus on US expansion and cannabinoid beverage markets.
Cyborg Score Rationale
Q1 Fiscal 2026 showed gross revenue of $97.3 million (+46% YoY) and net revenue of $63.5 million (+49% YoY), demonstrating robust growth. Adjusted EBITDA reached $5.3 million (+273% YoY), indicating improving profitability. The company maintains strong market leadership in Canada while scaling international operations, though cannabis market regulatory uncertainty poses ongoing risks.
Top Insights
Strong YoY revenue growth of 46% (gross) and 49% (net) in Q1 Fiscal 2026
International revenue grew 51% YoY to $5.0 million, indicating successful global expansion
Company achieved proprietary genetic screening breakthrough reducing powdery mildew resistance identification from months to days
James Yamanaka appointed as Chief Executive Officer, effective January 15, 2026
Named Competitors
Canopy Growth — Canadian cannabis producer with global presence
Tilray/Aphria — Cannabis producer with international operations
Trulieve — US-focused cannabis retailer and producer
Recent Developments
(February 2026) Q1 Fiscal 2026 results announced with 46% gross revenue growth to $97.3M and EBITDA up 273% YoY
(January 2026) James Yamanaka appointed as Chief Executive Officer
(December 2025) Launched happly, a U.S. hemp-derived THC brand with three low-dose vegan gummies formulated for Socialize, Relax, and Sleep
Open the full interactive Organigram Global Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.